Pharma

U.S. FDA approves Novartis' leukemia treatment

(Reuters) - The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday.<p>AML is a cancer that originates in the bone marrow and progresses rapidly, resulting in an …

Cancer

Cancer Drugs Fund condemned as expensive and ineffective

Treatments approved by David Cameron’s scheme were not worth money, extended life very little and often had adverse side-effects, study finds<p>The Cancer Drugs Fund, set up by the government to pay for expensive medicines that the NHS would not normally finance, failed to benefit patients and may …

Cancer

Sanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit

PARIS – French drugmaker Sanofi SA (SAN.FR) said first-quarter net profit jumped, boosted by the sale of its animal-health business.<p>On Friday, the Paris-based drugmaker said net profit rose to 5.7 billion euros ($6.2 billion) from EUR1.09 billion a year earlier.<p>Business net income, the company's …

Markets

The FDA Just Approved One of the Most Expensive Drugs in the World

Welcome to the latest drug price scandal: a rare disease treatment with a list price of more than $700,000 per year.<p>The Food and Drug Administration …

Medicine

These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016

If I told you that drug companies lean on their exceptional pricing power to grow their top and bottom lines, it probably wouldn't come as a shock in the least. If you've picked up a prescription from the pharmacy at any point over the past couple of years, you're probably well aware of the …

Stocks

Takeda's Ariad deal pays off with blockbuster green light for Alunbrig

Just two months after completing its deal to buy the Boston biotech Ariad, Takeda is getting a quick and important lift. On Friday, the FDA approved …

Cancer

Introducing the 'abortion pill,' which takes the clinic out of the equation

Allegations that anti-abortion protesters are harassing patients and staff headed into The Morgentaler Clinic on Bank Street have attracted attention …

Health Care

What's Worrying Me About Biogen

<b>Biogen Inc.</b> (NASDAQ: BIIB) recently reported its first-quarter financial results, and while the company remains the market share leader in multiple sclerosis (MS) treatment, there are signs that its dominance could be waning.<p>An increasingly competitive market<p>MS is a central nervous system disorder …

Stocks

Should over-the-counter medical abortion be available?

At the moment, the idea of over-the-counter access to medication abortion in the United States sounds crazy. But preliminary data suggests it is safe<p>The coat hanger – often with a red line through it – is a powerful feminist symbol. Conjuring images of women suffering unspeakable consequences of …

Women's News

AstraZeneca investors rebel—again—at CEO Pascal Soriot's 68% bonus-pay boost

AstraZeneca’s investors are repeating history with a revolt against executive pay. Almost 40% voted against CEO Pascal Soriot’s 2016 compensation …

Governance

Are NHS patients getting the best medicines?

<b>There's always a tension in decisions about purchasing medicines by the NHS.</b><p>On the one hand, getting the best value for taxpayers. And on the other, allowing sufficient incentives for drug companies to do business in the UK.<p>Right now, the UK's pharmaceutical industry - or "big pharma" - feels the …

NHS

Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S.

Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer …

Markets

Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund

Background<p>The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been …

Cancer

Drug Giant Sanofi May Be Getting Ready to Buy Up This Rare Disease Company

French pharma giant Sanofi has been trying its best to snap up assets in the face of falling sales and competition for its flagship diabetes drug …

Stocks

Ontario budget makes province first in Canada to offer free prescription drugs to everyone under 25

Print<p>More than four million Ontarians up to the age of 24 will receive free prescription drugs starting next year.<p>The province will become the first …

Canada

America’s Other Drug Problem

Every week in Des Moines, Iowa, the employees of a small nonprofit collect bins of unexpired prescription drugs tossed out by nursing homes after …

Health Care

AstraZeneca boss hails 'pivotal year' as revenue slips

AstraZeneca has reported another quarter of falling drug sales as it struggles with the loss of patents on some of its major medicines, but its chief executive has promised a fight back this year.<p>Product sales slid by 13pc in the first quarter of 2017 as the firm lost its dominance in the US …

Cancer

Insulin prices spike by 1123%, sending parents to the black market to keep their kids alive

Gabriella Corley is a 9 year old with Type I diabetes who's allergic to the insulin covered by her low-income parents' healthcare; to live, she must …

Black Market

Why the U.S. pays more for health care than the rest of the world

Watch Video | Listen to the Audio<b>JUDY WOODRUFF:</b> One of the big battles of the president’s first 100 days that remains unresolved is the fate of …

Health Care

FT Health: Moving beyond malaria

Tackling malaria, Joe Jimenez, medieval medicine

Medicine

Here’s What To Do If Your Birth Control Gets Crazy-Expensive

Finding a hormonal birth control that works for your lifestyle is tricky. And then, once you figure that out, you have to get a grip on how your health insurance works, and how much you should be paying for your prescription. It can be overwhelming, particularly right now, when there's something …

Pregnancy

AstraZeneca sales slide as Crestor patent expiry continues to bite

Total revenues fall 12% year-on-year to $5.4bn in January to March period.<p>AstraZeneca has reported a 12% fall in revenue for the first quarter on the …

Markets

Synairgen loses half its value as AstraZeneca dumps drug

LONDON (Reuters) - British biotech firm Synairgen lost nearly half its value on Thursday as partner AstraZeneca pulled the plug on an experimental drug designed to help patients fight common cold viruses.<p>AstraZeneca announced the decision to discontinue development of the inhaled interferon …

Medicine

New Glaxo CEO Seeks Tighter Drug Focus -- WSJ

GlaxoSmithKline PLC's new boss, Emma Walmsley, said Wednesday that she plans to narrow the company's drug research to focus only on the biggest opportunities.<p>Ms. Walmsley, who became chief executive on April 1, faces a sparse late-stage pipeline emptied by several recent drug launches. It falls to …

Markets

FDA approves Bayer's Stivarga to treat most common liver cancer

(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG's drug Stivarga to treat liver cancer, the first such approval in nearly a decade.<p>Stivarga is already approved to treat colorectal cancer in patients who have previously been treated with other therapies. …

Cancer

AstraZeneca Profit Drops on Decline in Blockbuster-Drug Revenue

AstraZeneca PLC said profit fell in the first quarter of the year as it battles declining sales of its blockbuster cholesterol pill.<p>Cambridge, England-based AstraZeneca said net profit fell 17% to $537 million in the three months to March 31, from $646 million a year earlier. Core operating profit, …

Markets

The 'Nissan letter' is proof lobbying pays off

We don't know what it will look like, how it will affect us, how much it will cost. But for all the uncertainty, there is one business that appears …

Brexit

Resurgent Humira sales make up for hep C decline, powering AbbVie to Q1 beat

AbbVie investors were jittery late last year as the company's mega-blockbuster Humira kept missing sales expectations overseas, especially when the …

Markets

As Supreme Court steps into tangled biosimilars law, IP experts weigh in

U.S. Supreme Court justices took their shot at picking apart the knotty Biologics Price Competition and Innovation Act on Wednesday, questioning …

Law

Amgen's Q1 Results Highlight the Need for an Acquisition

<b>Amgen</b> (NASDAQ: AMGN) has demonstrated a pretty good track record of beating Wall Street earnings estimates. The big biotech kept the streak going when it announced first-quarter results on Wednesday after the market closed.<p>However, those results also highlighted the importance of Amgen making an …

Stocks